[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340869-105":59,"doc-detail-340869-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-complex-role-of-il-10-in-malignant-ascites-a-review","The complex role of IL-10 in malignant ascites - a review","","Malignant ascites (MA) signals poor prognosis across ovarian, gastrointestinal, breast, and pancreatic cancers. Interleukin-10 (IL-10), a pleiotropic immunoregulatory cytokine in the tumor microenvironment, shows cancer-type and patient-dependent variation in MA and affects disease progression and outcomes. Produced by multiple immune and cancer cells, IL-10 drives complex signaling networks. Limited evidence supports systemic IL-10 administration, which may enhance CD8+ T-cell cytotoxicity and restore exhausted CD8+ tumor infiltration lymphocytes, and IL-10 blockade may work synergistically with other immunotherapies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-complex-role-of-il-10-in-malignant-ascites-a-review/340869/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-complex-role-of-il-10-in-malignant-ascites-a-review/340869.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is malignant ascites and why is it clinically important?","Question",{"text":113,"@type":114},"Malignant ascites is the accumulation of malignant cells in peritoneal fluid. It commonly causes abdominal swelling and symptoms that reduce quality of life and usually indicates an unfavorable prognosis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does IL-10 relate to the tumor microenvironment in malignant ascites?",{"text":118,"@type":114},"IL-10 is a pleiotropic cytokine with immunoregulatory effects in the tumor microenvironment. Its levels in MA vary by cancer type and patient, and it participates in complex signaling pathways that influence progression and outcomes.",{"name":120,"@type":111,"acceptedAnswer":121},"What therapeutic strategies targeting IL-10 in MA are discussed?",{"text":122,"@type":114},"Systemic IL-10 administration is described as a promising but limited-evidence approach, potentially increasing CD8+ T-cell cytotoxicity and reinvigorating exhausted CD8+ TILs. IL-10 signaling blockade is also highlighted as having potential, especially when combined with other immunotherapies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},340869,1790112552,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Cancer Immunology, Immunotherapy (2024) 73:32 [https://doi.org/10.1007/s00262-023-03616-y](https://doi.org/10.1007/s00262-023-03616-y)  \nThe complex role of IL‑10 in malignant ascites: a review  \nYue Huang1,2 · Kangni Zou1,2 · Heng Jiang3 · Zhengyu Li1,2  \nReceived: 20 September 2023 / Accepted: 5 December 2023 / Published online: 27 January 2024 © The Author(s) 2024  \nAbstract  \nThe emergence of malignant ascites (MA) indicates poor prognoses in patients with ovarian, gastrointestinal, breast, and pancreatic cancer. Interleukin-10 (IL-10) is a pleiotropic cytokine with immunoregulatory effects in tumor microenvironment. The level of IL-10 in MA varied across cancer types and patients, influencing cancer progression and outcomes. Originating from various immune and cancer cells, IL-10 contributes to complex signaling pathways in MA. Systemic IL-10 administration, although the evidence of its efficacy on MA is limited, still emerges as a promising therapeutic strategy because it can increase CD8+ T cells cytotoxicity and invigorate exhausted CD8+ tumor infiltration lymphocytes (TILs) directly. IL-10 signaling blockade also demonstrates great potential when combined with other immunotherapies in MA treatment. Wereviewed the levels, origins, and functions of IL-10 in malignant ascites and overviewed the current IL-10 signaling targeting therapies, aiming to provide insights for MA treatment.  \nKeywords Malignant ascites · Interleukin-10 · Immunotherapy · Tumor microenvironment  \nIntroduction  \nMalignant ascites (MA) is defined as the peritoneal fluid collection containing malignant cells in a cancer patient. Substantial amount of ascites can lead to abdominal swelling, nausea, early satiety, edema, pain, and even dyspnea, decreasing quality of life and usually indicating a unfavorable prognosis [1–3] . MA is commonly associated with primary abdomen or pelvic malignancies such as liver, colon, or ovarian cancers; it can also manifest in metastatic diseases. The precise molecular mechanisms underlying MA remain elusive, but increased vascular permeability and peritoneal lymphatic obstruction are recognized as key pathophysiological processes involving multiple cytokines.  \nYue Huang and Kangni Zou have contributed equally to this work.  \n* Zhengyu Li [Zhengyuli01@126.com](Zhengyuli01@126.com)  \n1 Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu 610041, People’s Republic of China  \n2 Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, People’s Republic of China  \n3 College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA  \nNotably, vascular endothelial growth factors (VEGF), a prominent vascular permeability factor, exhibit heightened expression in MA [4–7] . Additionally, other cytokines like tumor necrosis factor- , interleukin-6, interleukin-8, and interleukin-10 (IL-10) are elevated in the context of ovarian cancer (OC) patients with MA [8–10] . The intricate interplay of these cytokines may contribute to the impediment of fluid absorption and drainage, as tumor cells disseminate and proliferate within the peritoneal cavity, potentially obstructing lymphatic vessels [5, 11] . In addition to these primary mechanisms, neovascularization induced by matrix metalloproteinase (MMPs) and the retention of hypertonic fluids secreted by tumor may also play pivotal roles in the formation of MA [12–16](Figure S1) .  \nThere is no clear guidance on managing MA, but the treatments mainly fall into either relieving symptoms or controlling the primary diseases. Intermittent paracentesis is the most widely used intervention for controlling MA clinically, and its modified technique, cell-free and concentrated ascites reinfusion therapy is applied in Japan, which is thought to avoid protein loss compared with conventional paracentesis [17] . However, paracentesis relieves symptoms temporari","cbCaitvx2laGpU7W","https://ap.wps.com/l/cbCaitvx2laGpU7W","pdf",1379318,12,"English","# Introduction\n## Definition and clinical significance of malignant ascites\n## Pathophysiology and key cytokines in MA\n## Current management strategies and limitations","[{\"question\":\"What is malignant ascites and why is it clinically important?\",\"answer\":\"Malignant ascites is the accumulation of malignant cells in peritoneal fluid. It commonly causes abdominal swelling and symptoms that reduce quality of life and usually indicates an unfavorable prognosis.\"},{\"question\":\"How does IL-10 relate to the tumor microenvironment in malignant ascites?\",\"answer\":\"IL-10 is a pleiotropic cytokine with immunoregulatory effects in the tumor microenvironment. Its levels in MA vary by cancer type and patient, and it participates in complex signaling pathways that influence progression and outcomes.\"},{\"question\":\"What therapeutic strategies targeting IL-10 in MA are discussed?\",\"answer\":\"Systemic IL-10 administration is described as a promising but limited-evidence approach, potentially increasing CD8+ T-cell cytotoxicity and reinvigorating exhausted CD8+ TILs. IL-10 signaling blockade is also highlighted as having potential, especially when combined with other immunotherapies.\"}]","The complex role of IL-10 in malignant ascites - a review | PDF",1790039258,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfd5fe763a5e26647de66b78c58d9a36.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac68e2c00925db8f72a985ccc4c7110b.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd37d5bedcead5c372030644fed3a5c9.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edaae59c9b5a7077c896d622ac849b99.webp",980,1301]